Exploring the potential of finger prick blood for assessment of BIOmarkers for LOw Grade Inflammation and CVD risk

Completed

• Conditions: obesity; 10013317

• Registration Number: NL-OMON51003
• Lead Sponsor: Stichting Wageningen Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

* Age 18-70 years
* Living in the surroundings of Wageningen (max. 25 km)
* Stable body weight for past 6 months
* Suitable veins for insertion of cannula
-Specifically for lean subjects:
* BMI 18.5-22 kg/m2

-Specifically for obese subjects:
* BMI * 30 kg/m2

Exclusion Criteria

* Use of cholesterol-lowering medication
* Use of diabetes medication (e.g. insulin, metformin)
* Use of antibiotics or anti-inflammatory medication
* Known allergy for any of the food components used in the study (milk, cream,
sugars)
* Blood clotting disorders
* Current smokers
* Alcohol consumption of > 21 units per week

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Plasma levels of ApoB48 and LPS in both venous blood samples and finger prick<br /><br>blood collected under fasting conditions and in response to a high fat<br /><br>challenge test (1, 2, 4 and 6 hours post ingestion). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>